Methamphetamine (MA) use disorder poses a significant public health challenge, particularly given the rise in MA-involved overdoses over the past decade. Despite the severity of this issue, there is ...

JUPITER, Fla., April 28, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing innovative therapies for cancer and neurological disorders, today announced that it has been ...

Methamphetamine use , methamphetamine-related overdoses, and methamphetamine use disorder (MUD) are national problems that cause serious illness and death.. Making matters worse, methamphetamine is ...

Though overdose deaths continue to surge, there is no approved medication to treat methamphetamine use disorder. Now, an experimental two-drug therapy has yielded promising results, UCLA researchers ...

TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research ...

A new study published in the journal Science Signaling has found that an immune system protein plays a central role in the addictive mechanisms of methamphetamine. The findings suggest that tumor ...

A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment, UCLA-led research suggests.

There has been an "alarming" increase in mental health hospital admissions involving methamphetamine use, new research showed. Investigators found that between 2008 and 2020, such admissions increased ...

In urine tests for methamphetamine, drug-free results rose 27% among participants who received a combination of injectable naltrexone plus extended-release oral buproprion. Photo by Adobe ...